ENDRA Life Sciences- Warrants (12/05/2022) Operating Income

As of the most recent data (June 2026), NDRAW shows a operating income of $0. That compares with $5.8M in the prior-year period — down 100.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NDRAW's operating income is now $0 (was $5.8M) — a 100.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether ENDRA Life Sciences- Warrants (12/05/2022) is outperforming or lagging.

Tracking NDRAW's operating income over time shows whether ENDRA Life Sciences- Warrants (12/05/2022) is scaling, shrinking, or reshaping that part of the business. The current reading is $0 That compares with $5.8M in the prior-year period — down 100.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has ENDRA Life Sciences- Warrants (12/05/2022)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $0) with ownership activity and broader fundamentals.

ENDRA Life Sciences- Warrants (12/05/2022)'s operating income is $0; compare it with other Technology names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.